(Total Views: 433)
Posted On: 06/07/2020 9:01:59 AM
Post# of 36568
I can't find any update on this. Has the trial started? If not, why the delay?
From the Feb 2019 PR: Regentys is currently undertaking activities to initiate its first-in-human trials in Australia expected in the fourth quarter of 2019. “We believe there is a strong global need for our core technology. Patent approval in Japan enables the company to address the growing Asian market for therapies to treat mild to moderate UC and Crohn’s and other inflammatory bowel diseases (“IBD”),” said Rick Bulman, Chief Executive Officer of Regentys Corporation.
From the Feb 2019 PR: Regentys is currently undertaking activities to initiate its first-in-human trials in Australia expected in the fourth quarter of 2019. “We believe there is a strong global need for our core technology. Patent approval in Japan enables the company to address the growing Asian market for therapies to treat mild to moderate UC and Crohn’s and other inflammatory bowel diseases (“IBD”),” said Rick Bulman, Chief Executive Officer of Regentys Corporation.
(0)
(0)
